Wooly Mammoth startup Colossal seeking at least $20B valuation
De-extinction startup Colossal Biosciences is reportedly pursuing a new funding round with a target valuation between $20 billion and $30 billion.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Colossal Biosciences, a startup focused on the de-extinction of the wooly mammoth, is currently in talks to raise new capital. According to various reports, the company is seeking a valuation in the range of $20 billion to $30 billion for this upcoming funding round. This represents a significant leap in the company's perceived market value, with some reports indicating that this new target could be up to three times the valuation of its previous funding round. The company is utilizing its specialized focus on bringing back extinct species to attract substantial investor interest at this time. Coverage of this financial move is widespread across several technology and business news outlets. TechCrunch and Axios have both reported that the startup is seeking at least a $20 billion valuation.
Similarly, the news organization XenoSpectrum has highlighted that the discussions involve a range between $20 billion and $30 billion, specifically noting the potential three-fold increase over previous rounds. Other outlets reporting on the matter include Seeking Alpha, which linked the report to market interests, as well as Zamin.uz and Межа. Новини України, both of which emphasize the potential for the company to reach the higher $30 billion mark. To understand the significance of this trend, it is necessary to recognize the unique nature of Colossal Biosciences as a de-extinction startup. The company's primary goal involves the complex biological task of recreating the wooly mammoth, a project that requires immense capital and advanced genetic technology. The pursuit of a valuation exceeding $20 billion suggests a high level of investor confidence in the technical feasibility of de-extinction or the broader applications of the biotechnology being developed by the firm. This valuation would place the startup in a high-tier bracket of biotechnology ventures globally.
Looking forward, the primary point of observation will be whether Colossal Biosciences successfully secures the funding at the reported $20 billion to $30 billion range. Because the coverage is based on reports of ongoing talks, the final valuation will confirm the actual market appetite for de-extinction technology. Observers will be watching for official confirmation from the company regarding the exact amount of capital being raised and the final valuation agreed upon with investors. Coverage does not yet specify the names of the specific investors involved in these current funding discussions.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 111d ago.
Quick answers
What valuation is Colossal Biosciences seeking?
The company is reportedly in talks for a valuation between $20 billion and $30 billion.
How does this valuation compare to previous rounds?
According to XenoSpectrum, the new valuation could be up to three times higher than the previous round.
What is the primary focus of Colossal Biosciences?
Colossal Biosciences is a de-extinction startup focusing on the wooly mammoth.
Coverage (6)
- Colossal Reportedly in Talks to Raise Funding at $20B–$30B Valuation, Up to 3x Previous Round XenoSpectrum · 116d ago
- Colossal Biosciences seeks 20 to 30 billion valuation in new funding round Межа. Новини України. · 117d ago
- Colossal Biosciences, the de-extinction startup, could reach a $30 billion valuation Zamin.uz · 117d ago
- Colossal Biosciences discussing new funding at $20B or more valuation: report (IBB:NASDAQ) Seeking Alpha · 117d ago
- Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation TechCrunch · 117d ago
- Wooly Mammoth startup Colossal seeking at least $20B valuation Axios · 117d ago
Topics
Related trends
Anthropic IPO could draw record retail buyers, Vanda Research says
Anthropic's impending IPO may attract unprecedented retail investor participation according to Vanda Research analysis.
Here's Why The Dire Wolf Really Wasn't Brought Back From Extinction, Scientists Argue
Scientists push back on claims that dire wolves have been resurrected, arguing the animals are genetically modified gray wolves, not true de-extinction.
Sequoia hits rewind, undoing 20 years of expansion
Venture capital firm Sequoia Capital is undoing two decades of global expansion by closing its London office and flattening its partner structure.
Baseten Set for $30 Billion Valuation With New Funding
AI infrastructure provider Baseten is approaching a $30 billion valuation following a new round of funding.
B-Vitamin Supplement Can Treat Psoriasis, a Skin Condition with No Cure
A cheap B‑vitamin pill shows promise in easing psoriasis symptoms, sparking hope for millions with the incurable skin disease
Anthropic's latest biotech buy is a one-man stealth startup run by a pseudonymous Twitter poster
Anthropic is expanding its biotech footprint by acquiring a stealth, one-person startup operated by a pseudonymous Twitter user.